Guillain-Barré syndrome nursing: assessment, interventions, and NCLEX tips

Guillain-Barré syndrome (GBS) is the most common cause of acute, flaccid neuromuscular paralysis in the United States, affecting 0.4 to 2 people per 100,000 annually. It is a post-infectious autoimmune polyneuropathy in which the immune system attacks peripheral nerve myelin (and in some subtypes, axons directly), producing rapid ascending weakness that can escalate from foot weakness to respiratory failure within days. Up to 30% of patients require mechanical ventilation. For nursing students, GBS is high-yield NCLEX material because it demands integration of respiratory monitoring priorities, autonomic instability management, pharmacological decision-making between IVIG and plasmapheresis, and understanding of why corticosteroids — an intuitive treatment — are contraindicated. This reference covers pathophysiology, subtypes, clinical presentation, diagnostic criteria, disease progression, nursing assessment, nursing interventions, pharmacology, and ten NCLEX-focused clinical reasoning patterns.

Quick reference: GBS at a glance

Pathophysiology

GBS develops through a process of molecular mimicry following infection. The triggering pathogen — most often Campylobacter jejuni, but also Epstein-Barr virus, cytomegalovirus (CMV), HIV, Mycoplasma pneumoniae, and influenza — displays surface structures (particularly lipooligosaccharides in C. jejuni) that closely resemble ganglioside components of peripheral nerve myelin. The immune system mounts an appropriate response to the pathogen, but the antibodies and activated T cells it generates cross-react with nerve tissue.

In the most common subtype (AIDP), autoreactive T cells and antibodies target the myelin sheaths produced by Schwann cells in the peripheral nervous system. Complement-mediated attack strips myelin from axons, disrupting saltatory conduction (the jumping of electrical signals between nodes of Ranvier). The result is dramatically slowed nerve conduction velocity and failure of neural signaling — manifesting clinically as weakness, sensory loss, and areflexia.

Crucially, GBS affects the peripheral nervous system, not the CNS. This distinguishes it from conditions like multiple sclerosis and ALS, where CNS involvement drives symptoms. Because Schwann cells can regenerate and remyelinate, most patients recover — though the process takes months and recovery is incomplete in a minority.

GBS subtypes

Miller Fisher syndrome deserves special attention for NCLEX. It begins with double vision and eyelid drooping, progresses to ataxia and loss of deep tendon reflexes, but characteristically does not cause ascending limb paralysis. Anti-GQ1b antibodies are highly specific (>90% sensitivity). The cranial nerve involvement — particularly the extraocular muscles — reflects the dense distribution of GQ1b ganglioside at those nerve terminals.

Clinical presentation

Ascending weakness

The hallmark of classic GBS is symmetric ascending weakness beginning in the distal lower extremities and progressing proximally. The patient typically first notices difficulty climbing stairs or rising from a chair, progressing over days to proximal leg weakness, then arm involvement, and finally cranial nerve dysfunction. This ascending pattern distinguishes GBS from conditions like stroke (sudden unilateral) and spinal cord injury (level-dependent, often with preserved distal function below a clear dermatomal boundary).

Sensory symptoms often precede motor weakness. Patients report paresthesias (tingling, numbness), dysesthesias (burning pain), and deep aching back pain — the back pain is frequently underrecognized and can be severe. Sensory deficits on examination tend to be mild relative to the profound motor weakness.

Cranial nerve involvement

Cranial nerves are affected in about 50% of GBS cases. The most common findings:

• Facial nerve (CN VII): Bilateral facial weakness (facial diplegia) — drooping on both sides, inability to close eyes fully, reduced smile
• Vagal and glossopharyngeal (CN IX/X): Dysphagia and impaired gag reflex — aspiration risk
• Oculomotor nerves (CN III, IV, VI): Ophthalmoplegia (especially in MFS variant)

Bulbar dysfunction (dysphagia, dysarthria) signals that the patient needs swallowing evaluation and aspiration precautions immediately.

Autonomic dysfunction

Autonomic instability occurs in approximately two-thirds of GBS patients and is the leading cause of GBS morbidity and mortality outside of respiratory failure. Manifestations include:

• Cardiovascular: Wide BP swings (both hypertension and hypotension), tachycardia, bradycardia, heart block, asystole
• Urinary: Urinary retention (bladder atony)
• Gastrointestinal: Ileus, constipation
• Sudomotor: Anhidrosis or diaphoresis
• Endocrine: SIADH — occurring in up to 48% of patients, causing hyponatremia

Autonomic swings in GBS can be extreme and unpredictable. Blood pressure may oscillate between 60/40 and 200/100 within hours. Sinus bradycardia can degenerate to asystole during suctioning or position changes. This is why continuous cardiac monitoring and ICU-level vigilance are standard of care.

Respiratory compromise

Respiratory failure is the most feared complication of GBS, occurring in 25–30% of patients. It develops as ascending weakness reaches the intercostal muscles and diaphragm. The patient may not report breathlessness until respiratory reserve is critically reduced — so nurses must not rely on subjective reporting alone. Serial objective measurements are essential (see Nursing assessment, below).

Diagnostic criteria

GBS is diagnosed primarily clinically, but several investigations support and confirm the diagnosis.

Brighton criteria provide a standardized framework stratifying diagnostic certainty from Level 1 (highest — bilateral flaccid limb weakness + decreased/absent deep tendon reflexes in weak limbs + monophasic course + interval 12 hours to 28 days to nadir + CSF albuminocytologic dissociation + electrodiagnostic evidence) down to Level 4 (insufficient data).

CSF findings — albuminocytologic dissociation: This is the pathognomonic CSF pattern in GBS: elevated total protein (>45 mg/dL) with normal or near-normal WBC count (<10 cells/µL). It reflects protein leaking from inflamed nerve roots into the CSF without an inflammatory cell pleocytosis. Importantly, CSF protein may be normal in the first 4 days of illness — it becomes elevated in 70–90% of patients by the end of week 2. A lumbar puncture that comes back normal early in the course does not rule out GBS.

Electrodiagnostic studies (nerve conduction studies / EMG):

• AIDP: Slowed conduction velocity, prolonged F-wave latency, conduction block, dispersion of CMAP — all reflecting demyelination
• AMAN/AMSAN: Reduced CMAP amplitude with normal (or near-normal) conduction velocity — axonal pattern
• The “sural-sparing” pattern (preserved sural nerve responses with absent median/ulnar sensory responses) favors GBS over other neuropathies

Anti-ganglioside antibodies:

• Anti-GQ1b: Present in >90% of Miller Fisher syndrome cases
• Anti-GM1, anti-GD1a: Associated with AMAN subtype, often post-C. jejuni

Disease progression: three phases

GBS follows a predictable three-phase course, though the speed and severity of each phase vary considerably.

Phase 1 — Progressive phase (days to 4 weeks): Weakness escalates from initial symptoms to nadir. By definition, GBS reaches its worst point within 4 weeks; if progression continues beyond 8 weeks, the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) should be considered. This is the highest-risk phase for respiratory failure and autonomic instability.

Phase 2 — Plateau phase (days to weeks): The patient has reached maximum weakness and clinical status stabilizes. This phase can last days to several weeks. Ongoing monitoring for complications (DVT, aspiration, pressure injury, pain, psychological distress) is the nursing focus.

Phase 3 — Recovery phase (weeks to months): Remyelination and axonal sprouting allow gradual return of function, proceeding in reverse order (proximal before distal). Most patients show significant improvement within 6 months. About 20% are left with significant residual disability.

The 20-30-40 rule for respiratory monitoring: Intubation is indicated when ANY of the following thresholds is crossed:

• Forced vital capacity (FVC) < 20 mL/kg
• Negative inspiratory force (NIF) worse than −30 cmH₂O (i.e., less negative — e.g., −20 cmH₂O)
• Maximum expiratory pressure (MEP) < 40 cmH₂O

This rule is critical for NCLEX. GBS patients can deteriorate rapidly to respiratory arrest without meeting standard SpO₂ or RR thresholds — their SpO₂ may remain normal until they are completely unable to generate a breath. FVC and NIF are the early warning system.

Nursing assessment

1. Respiratory function (absolute priority)

Respiratory assessment is the single highest nursing priority in GBS. Perform and document serially:

• FVC — bedside spirometry; threshold for intubation: <20 mL/kg
• NIF (negative inspiratory force) — threshold: worse than −30 cmH₂O
• MEP (maximum expiratory pressure) — threshold: <40 cmH₂O
• Respiratory rate, depth, and effort — accessory muscle use, paradoxical breathing
• SpO₂ — note this is a late indicator; do not rely on it as the primary screen
• Dyspnea at rest — if present, prepare for urgent airway management
• Count-to-20 test — ask patient to count to 20 on one breath; inability to reach 20 in a single breath indicates reduced pulmonary reserve
• Ability to cough effectively — relevant to secretion clearance and aspiration risk

Any rapid deterioration in FVC or NIF should trigger immediate physician/provider notification. A trending downward FVC — even if not yet at the 20 mL/kg threshold — signals an accelerating trajectory that may demand proactive intubation.

2. Cranial nerve assessment

• CN VII: Facial symmetry, ability to close eyes completely, smile — facial diplegia assessment
• CN IX/X: Gag reflex, ability to swallow without coughing, voice quality (wet/gurgling voice suggests aspiration)
• CN III/IV/VI: Eye movements, ptosis, diplopia (especially in MFS)
• Bedside swallowing screen before any oral intake

3. Motor assessment

• Symmetry and distribution of weakness — document proximal vs distal, arms vs legs
• Muscle strength grading (MRC scale 0–5) — track progression
• Deep tendon reflexes — areflexia or hyporeflexia is hallmark of GBS; document bilaterally
• Assess ability to ambulate, transfer, turn self, reposition

4. Autonomic instability monitoring

• Continuous cardiac monitoring — watch for bradycardia, heart block, tachyarrhythmias
• BP every 1–4 hours or continuous arterial line in severe cases
• I&O strict — bladder scan or catheterization for urinary retention
• Sodium — monitor for SIADH-related hyponatremia
• Bowel function — ileus/constipation management

5. Sensory and pain assessment

GBS pain is often underestimated. Types:

• Neuropathic pain — burning, electric, dysesthetic; requires neuropathic agents (not opioids alone)
• Deep aching back pain — common early symptom, may be the presenting complaint
• Musculoskeletal pain — from immobility, positioning

Use a validated pain scale and specifically assess for neuropathic quality. Patients who cannot communicate (intubated, facial weakness) need the Glasgow Coma Scale and behavioral pain tools.

6. Additional assessments

• DVT risk — immobility + autonomic neuropathy = elevated risk; assess for calf tenderness, edema
• Skin integrity — pressure injury risk from immobility and sensory loss; Braden scale
• Nutritional status — weight, albumin, dysphagia screening
• Psychosocial — GBS is a terrifying diagnosis for patients who may be fully cognitively intact but completely paralyzed; anxiety, depression, and PTSD are common
• Communication — document the patient’s best communication modality as weakness progresses

Nursing interventions

Airway and respiratory management

• Position head of bed at 30–45° to reduce aspiration risk and improve diaphragmatic excursion
• Keep suction at bedside; suction PRN — do not delay
• Serial FVC and NIF every 2–4 hours in progressive phase; more frequently if trending downward
• Anticipate and prepare for intubation — GBS respiratory failure can be sudden; have airway equipment ready
• Consider BiPAP/NIV as a bridge in patients with borderline respiratory parameters and adequate bulbar function (contraindicated if dysphagia is significant — risk of aspiration with NIV mask)
• After intubation, tracheostomy timing is typically discussed if ventilator dependence extends beyond 2 weeks
• Chest physiotherapy, incentive spirometry (as able), and frequent repositioning to prevent atelectasis and pneumonia

Autonomic management (critical)

• Avoid Valsalva-inducing activities (straining, coughing, breath-holding) — vagal stimulation can precipitate severe bradycardia or asystole
• Avoid Trendelenburg positioning — BP lability means this can unpredictably worsen hypotension or cause hypertensive overshoot
• Avoid rapid position changes — orthostatic hypotension is pronounced; move patients slowly
• No aggressive IV fluid boluses without close monitoring — cardiac function may be compromised
• Continuous cardiac monitoring with alerting parameters for HR <50 or >120 bpm, and arrhythmias
• Antihypertensive and vasopressor agents should be readily available but used cautiously — BP swings can reverse direction rapidly
• Treat hypertension only if sustained (not reactive peaks) to avoid inducing hypotension

DVT prophylaxis

• Enoxaparin (LMWH) is the preferred pharmacological agent — initiate early in the admission unless contraindicated
• Sequential compression devices (SCDs) on lower extremities — apply whenever not ambulating
• Passive range-of-motion exercises; early mobilization when clinically stable
• Monitor for DVT signs: calf warmth, swelling, Homans sign (limited sensitivity but document)

Pain management

• Gabapentin (300–1,200 mg TID) and pregabalin are first-line for neuropathic pain
• Tricyclic antidepressants (amitriptyline) may be used for neuropathic pain — note anticholinergic effects may worsen urinary retention
• Opioids have a role for severe pain but address neuropathic components inadequately alone; use cautiously given autonomic instability
• NSAIDs — use with caution in severe GBS; avoid in patients with renal compromise or high DVT anticoagulation requirements
• Reposition frequently — pressure-related pain from immobility is underrecognized
• Non-pharmacological: heat/cold, positioning, distraction, relaxation

Nutritional support

• Screen for dysphagia before permitting oral intake
• If swallowing is impaired: insert nasogastric tube (NGT) for enteral nutrition
• In prolonged intubation: percutaneous endoscopic gastrostomy (PEG) may be considered
• Daily caloric goals, with protein optimization for muscle recovery
• Oral care every 4 hours regardless of feeding route — reduces aspiration pneumonia risk

Communication

• GBS patients who are intubated or have facial diplegia remain fully cognitively intact
• Establish communication system early: eye gaze, blink codes, letter boards, or electronic devices
• Coordinate with speech-language pathology for communication device assessment
• Explain every intervention before performing it — the experience of being paralyzed and unable to communicate is profoundly distressing

Psychological support and rehabilitation planning

• Validate the patient’s fear and grief — GBS is a sudden, extreme loss of function in previously healthy individuals
• Early psychiatric or psychology consultation if anxiety or PTSD symptoms emerge
• Family education: GBS is temporary in most cases; recovery, though slow, is expected
• Begin rehabilitation planning (physical therapy, occupational therapy) during the plateau phase
• Average time to independent walking: approximately 6 months; some patients require longer

Pharmacology

IVIG vs plasmapheresis: choosing between them

Both IVIG and plasma exchange (PLEX) are equally effective first-line treatments for GBS when started within 2 weeks of symptom onset. Neither is clearly superior in clinical trials. Combining the two treatments does not improve outcomes beyond either alone.

IgA deficiency and IVIG: Patients with IgA deficiency can develop anaphylaxis when given IVIG because standard pooled immunoglobulin contains trace IgA and they may have anti-IgA antibodies. Always check IgA levels before administering IVIG. If IgA-deficient, either use IgA-depleted IVIG preparations or switch to plasmapheresis.

Complications

Ten NCLEX-focused tips

1. Respiratory monitoring is always the first nursing priority. Before any other concern, the nurse monitors respiratory status using objective measures — FVC, NIF, MEP — not just pulse oximetry or respiratory rate. GBS can cause respiratory arrest with normal SpO₂ right up to the moment of failure. The 20-30-40 rule (FVC <20 mL/kg, NIF worse than −30 cmH₂O, MEP <40 cmH₂O) triggers preparation for intubation.

2. Corticosteroids are not used in GBS — and may make it worse. This is one of the most tested NCLEX traps in GBS. Corticosteroids are the intuitive answer because GBS is autoimmune — but clinical trials have shown they provide no benefit over placebo and may worsen long-term outcomes. If a question asks what medication to anticipate, the correct answers are IVIG or plasmapheresis, not methylprednisolone.

3. Ascending pattern distinguishes GBS from descending conditions. GBS weakness ascends (legs → trunk → arms → cranial nerves). Botulism weakness descends (cranial nerves first → arms → trunk → legs). Knowing this direction is frequently tested.

4. IgA deficiency is a contraindication to IVIG. Before administering IVIG, the nurse checks the IgA level. Patients with IgA deficiency have anti-IgA antibodies and can have anaphylactic reactions to standard IVIG preparations. The alternative is IgA-depleted IVIG or plasmapheresis.

5. Plasmapheresis monitoring: watch for hypocalcemia. Plasmapheresis uses citrate as an anticoagulant. Citrate chelates ionized calcium, causing symptomatic hypocalcemia: perioral tingling is the earliest sign, progressing to muscle cramps, tetany, and (severely) cardiac arrhythmias with QT prolongation. The nurse monitors ionized calcium and reports perioral tingling immediately.

6. Autonomic instability demands continuous cardiac monitoring. BP swings in GBS can be extreme — patients may alternate between hypertension (systolic >200) and hypotension (systolic <80) within hours. Sinus bradycardia can degenerate to asystole during suctioning or Valsalva. GBS patients in the progressive phase require continuous cardiac monitoring and ICU-level care.

7. Albuminocytologic dissociation is the CSF hallmark. High protein + normal WBC in CSF = albuminocytologic dissociation = GBS until proven otherwise. This distinguishes GBS from bacterial meningitis (high protein + high WBC) and viral meningitis (normal or mildly elevated protein + lymphocytic pleocytosis). Note: CSF protein may be normal in the first 3–4 days.

8. Miller Fisher syndrome presents with the classic triad. Ophthalmoplegia + ataxia + areflexia — without ascending limb paralysis. Anti-GQ1b antibody is >90% sensitive. If an NCLEX question describes diplopia, eyelid drooping, unsteady gait, and absent reflexes after a respiratory illness, think Miller Fisher variant. Respiratory failure is less common but can still occur.

9. Pain management requires neuropathic agents, not opioids alone. GBS pain is neuropathic (burning, electric, shooting). Opioids alone are insufficient — they address nociceptive pain pathways but not the ectopic signaling of damaged peripheral nerves. First-line agents are gabapentin or pregabalin. NCLEX questions about GBS pain management expect knowledge of neuropathic pain pharmacology.

10. Recovery is slow — set expectations correctly. The average time to independent walking after GBS is approximately 6 months. At 1 year, more than 50% of patients have fully recovered, and >85% eventually regain independent ambulation. However, fatigue, neuropathic pain, and reduced exercise tolerance may persist for years. NCLEX may test patient education: the nurse should not say “you’ll be back to normal in a few weeks.”

Nursing diagnoses and care priorities

The following nursing diagnoses guide care planning in GBS, listed in priority order for the acute phase:

1. Ineffective breathing pattern — related to ascending neuromuscular weakness affecting respiratory muscles
2. Impaired physical mobility — related to ascending flaccid paralysis
3. Impaired swallowing — related to cranial nerve involvement (CN IX/X)
4. Acute pain — related to peripheral nerve inflammation (neuropathic and musculoskeletal)
5. Risk for aspiration — related to dysphagia, reduced gag reflex, and immobility
6. Risk for infection — related to immobility, invasive devices, immunotherapy
7. Impaired verbal communication — related to facial weakness and/or intubation
8. Anxiety and fear — related to sudden paralysis, uncertain prognosis, and dependence
9. Risk for impaired skin integrity — related to immobility and sensory deficits
10. Deficient knowledge — related to GBS course, treatment rationale, and recovery timeline

For comprehensive assessment frameworks, see the head-to-toe assessment guide and Glasgow Coma Scale reference for monitoring cognitively intact but physically compromised patients.

Related neurological nursing references

GBS is frequently tested alongside other acute and chronic neuromuscular conditions. Cross-reference these pages to build a complete picture of neurological nursing:

• Multiple sclerosis nursing — CNS demyelination (contrast with GBS peripheral demyelination); different treatment, chronic vs acute
• ALS nursing reference — progressive motor neuron disease; respiratory failure management and NIV parallels
• Myasthenia gravis nursing — NMJ disorder; IVIG and PLEX also used; myasthenic vs cholinergic crisis distinction
• Spinal cord injury nursing — level-dependent motor/sensory loss; neurogenic shock and autonomic dysreflexia
• Seizure nursing — GBS patients on high-dose IVIG or with hyponatremia (SIADH) have elevated seizure risk
• Stroke nursing — sudden focal neurological deficits; rule out in the GBS differential (GBS is symmetric and ascending; stroke is typically unilateral and sudden)